{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T07:10:02Z","timestamp":1755846602269,"version":"3.44.0"},"publisher-location":"New York, NY, USA","reference-count":40,"publisher":"ACM","license":[{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.acm.org\/publications\/policies\/copyright_policy#Background"}],"content-domain":{"domain":["dl.acm.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,13]]},"DOI":"10.1145\/3570773.3570784","type":"proceedings-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T15:57:42Z","timestamp":1670601462000},"page":"30-35","update-policy":"https:\/\/doi.org\/10.1145\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Research status and prospect of immune checkpoint inhibitors for melanoma"],"prefix":"10.1145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4306-3699","authenticated-orcid":false,"given":"Yuyi","family":"Liang","sequence":"first","affiliation":[{"name":"155 Consumers Rd Unit 108, Canada"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8539-7286","authenticated-orcid":false,"given":"Tianshi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Zhongshan Hospital, Fudan University, China"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0274-3305","authenticated-orcid":false,"given":"Yifan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of clinical medicine in Chinese and Western Medicine, Tianjin University of Traditional Chinese Medicine, China"}]}],"member":"320","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"key":"e_1_3_2_1_1_1","first-page":"51","article-title":"Mihm Jr. \"Melanoma","volume":"1","year":"2006","unstructured":"Miller, Arlo J., and Martin C. Mihm Jr. \"Melanoma.\"\u00a0New England Journal of Medicine 355.1, 2006: 51-65.","journal-title":"\u00a0New England Journal of Medicine 355"},{"key":"e_1_3_2_1_2_1","first-page":"971","article-title":"Melanoma","volume":"10151","year":"2018","unstructured":"Schadendorf, Dirk, \"Melanoma.\" The Lancet 392.10151, 2018: 971-984.","journal-title":"The Lancet 392"},{"key":"e_1_3_2_1_3_1","first-page":"275","article-title":"Focus on melanoma","volume":"4","year":"2002","unstructured":"Houghton, Alan N., and David Polsky. \"Focus on melanoma.\" Cancer cell 2.4, 2002: 275-278.","journal-title":"Cancer cell 2"},{"key":"e_1_3_2_1_4_1","first-page":"171","article-title":"Cutaneous melanoma","volume":"3","author":"K.","year":"1991","unstructured":"Koh, Howard K. \"Cutaneous melanoma.\" New England Journal of Medicine 325.3, 1991: 171-182.","journal-title":"New England Journal of Medicine 325"},{"key":"e_1_3_2_1_5_1","first-page":"673","article-title":"Non-melanoma skin cancer","volume":"9715","year":"2010","unstructured":"Madan, Vishal, John T. Lear, and Rolf-Markus Szeimies. \"Non-melanoma skin cancer.\" The lancet 375.9715, 2010: 673-685.","journal-title":"The lancet 375"},{"key":"e_1_3_2_1_6_1","first-page":"43","article-title":"Non-melanoma skin cancer incidence and impact of skin cancer screening on incidence","volume":"1","year":"2014","unstructured":"Eisemann, Nora, \"Non-melanoma skin cancer incidence and impact of skin cancer screening on incidence.\" Journal of Investigative Dermatology 134.1, 2014: 43-50.","journal-title":"Journal of Investigative Dermatology 134"},{"key":"e_1_3_2_1_7_1","first-page":"913","article-title":"Oxidative stress in malignant melanoma and non\u2010melanoma skin cancer","volume":"5","author":"S.","year":"2003","unstructured":"Sander, C. S., \"Oxidative stress in malignant melanoma and non\u2010melanoma skin cancer.\" British Journal of Dermatology 148.5, 2003: 913-922.","journal-title":"British Journal of Dermatology 148"},{"key":"e_1_3_2_1_8_1","doi-asserted-by":"crossref","unstructured":"Sanlorenzo Martina \"Melanoma immunotherapy.\" Cancer biology & therapy 15.6 2014: 665-674.","DOI":"10.4161\/cbt.28555"},{"key":"e_1_3_2_1_9_1","first-page":"61","article-title":"Immunotherapy of melanoma","volume":"1","year":"2018","unstructured":"Lugowska, Iwona, Pawel Teterycz, and Piotr Rutkowski. \"Immunotherapy of melanoma.\" Contemporary Oncology 22.1A, 2018: 61.","journal-title":"Contemporary Oncology 22"},{"key":"e_1_3_2_1_10_1","first-page":"1","article-title":"\"The use of immunotherapy in the treatment of melanoma","volume":"1","year":"2017","unstructured":"Achkar, Tala, and Ahmad A. Tarhini. \"The use of immunotherapy in the treatment of melanoma.\" Journal of hematology & oncology 10.1, 2017: 1-9.","journal-title":"Journal of hematology & oncology 10"},{"volume-title":"the changing landscape.\" Cancer management and research 6","year":"2014","key":"e_1_3_2_1_11_1","unstructured":"Srivastava, Neeharika, and David McDermott. \"Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape.\" Cancer management and research 6, 2014: 279."},{"key":"e_1_3_2_1_12_1","first-page":"3445","article-title":"Next generation of immunotherapy for melanoma","volume":"20","author":"M.","year":"2008","unstructured":"Kirkwood, John M., \"Next generation of immunotherapy for melanoma.\" Journal of Clinical Oncology 26.20, 2008: 3445-3455.","journal-title":"Journal of Clinical Oncology 26"},{"key":"e_1_3_2_1_13_1","first-page":"3446","article-title":"The MAPK pathway across different malignancies: a new perspective","volume":"22","year":"2014","unstructured":"Burotto, Mauricio, \"The MAPK pathway across different malignancies: a new perspective.\" Cancer 120.22, 2014: 3446-3456.","journal-title":"Cancer 120"},{"key":"e_1_3_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1556-0864(15)31506-9"},{"key":"e_1_3_2_1_15_1","first-page":"2516","article-title":"Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF\u2013MEK\u2013ERK pathway in cancer","volume":"10","author":"L.","year":"2014","unstructured":"Johnson, Gary L., \"Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF\u2013MEK\u2013ERK pathway in cancer.\" Clinical Cancer Research 20.10, 2014: 2516-2522.","journal-title":"Clinical Cancer Research 20"},{"key":"e_1_3_2_1_16_1","doi-asserted-by":"crossref","unstructured":"Warren Cody J Xu Tao Guo Kejun Griffin Laura M Westrich Joseph A Lee Denis Lambert Paul F Santiago Mario L Pyeon Dohun. APOBEC3A functions as a restriction factor of human papillomavirus. [J]. Journal of virology 2015 89(1):","DOI":"10.1128\/JVI.02383-14"},{"key":"e_1_3_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.001"},{"issue":"01","key":"e_1_3_2_1_18_1","first-page":"13","article-title":"Tumor immunoassay point treatment and its drug delivery strategy [J]","volume":"57","year":"2022","unstructured":"Li Peishan, Liu Yixuan, Xie Ying, Ren Yuxin, Chen Ming, Wang Guiling, Lu Wanliang. Tumor immunoassay point treatment and its drug delivery strategy [J]. Journal of Pharmacy, 2022, 57(01):13-24+275.","journal-title":"Journal of Pharmacy"},{"key":"e_1_3_2_1_19_1","volume-title":"Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol","author":"JJ S","year":"2015","unstructured":"Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, Garbe C, Chiarion-Sileni V, Testori A, Chen TT, Tschaika M, Wolchok JD. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. 2015, Apr 1;33(10):1191-6."},{"key":"e_1_3_2_1_20_1","volume-title":"Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy [published correction appears in N Engl J Med","author":"AM V","year":"2018","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy [published correction appears in N Engl J Med. 2018, Nov 29;379(22):2185]. N Engl J Med. 2016;375(19):1845-1855."},{"key":"e_1_3_2_1_21_1","first-page":"3937","author":"GV B","year":"2020","unstructured":"Robert C, Long GV, Brady B, Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma. J Clin Oncol. 2020;38(33): 3937-3946.","journal-title":"J Clin Oncol."},{"key":"e_1_3_2_1_22_1","unstructured":"Wolchok JD Chiarion-Sileni V Gonzalez R Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma [published correction appears in N Engl J Med. 2018 Nov 29;379(22):2185]. N Engl J Med. 2017;377(14):1345-1356."},{"key":"e_1_3_2_1_23_1","doi-asserted-by":"crossref","unstructured":"Ribas A Puzanov I Dummer R Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised controlled phase 2 trial. Lancet Oncol. 2015;16(8):908-918.","DOI":"10.1016\/S1470-2045(15)00083-2"},{"key":"e_1_3_2_1_24_1","doi-asserted-by":"crossref","unstructured":"Robert C Ribas A Schachter J Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label multicentre randomised controlled phase 3 study. Lancet Oncol. 2019;20(9):1239-1251.","DOI":"10.1016\/S1470-2045(19)30388-2"},{"key":"e_1_3_2_1_25_1","doi-asserted-by":"crossref","unstructured":"Robert C Long GV Brady B Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320-330.","DOI":"10.1056\/NEJMoa1412082"},{"key":"e_1_3_2_1_26_1","unstructured":"Larkin J Chiarion-Sileni V Gonzalez R Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma [published correction appears in N Engl J Med. 2018 Nov 29;379(22):2185]. N Engl J Med. 2015;373(1):23-34."},{"key":"e_1_3_2_1_27_1","doi-asserted-by":"crossref","unstructured":"Schreiber RD Old LJ Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331(6024):1565-1570.","DOI":"10.1126\/science.1203486"},{"key":"e_1_3_2_1_28_1","volume-title":"Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance [J]. Prostate cancer and prostatic diseases","author":"MARTIN A M","year":"2015","unstructured":"MARTIN A M, NIRSCHL T R, NIRSCHL C J, Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance [J]. Prostate cancer and prostatic diseases, 2015, 18(4): 325-32."},{"issue":"09","key":"e_1_3_2_1_29_1","first-page":"1053","article-title":"Research status and prospect of immunotherapy for melanoma [J]","volume":"26","year":"2021","unstructured":"Li Wei, Hu Jiali, Wang Kai and He Yijing. Research status and prospect of immunotherapy for melanoma [J]. Clinical Pharmacology and Therapy in China, 2021, 26(09):1053-1064.","journal-title":"Clinical Pharmacology and Therapy in China"},{"key":"e_1_3_2_1_30_1","volume-title":"Immunotherapy and patients treated for cancer with microsatellite instability [J]. Bulletin du cancer","author":"COLLE R","year":"2017","unstructured":"COLLE R, COHEN R, COCHEREAU D, Immunotherapy and patients treated for cancer with microsatellite instability [J]. Bulletin du cancer, 2017, 104(1): 42-51."},{"key":"e_1_3_2_1_31_1","doi-asserted-by":"crossref","unstructured":"LIU C PENG W XU C BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice [J]. Clinical cancer research: an official journal of the American Association for Cancer Research 2013 19(2): 393-403.","DOI":"10.1158\/1078-0432.CCR-12-1626"},{"key":"e_1_3_2_1_32_1","volume-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling [J]. Nature reviews Immunology","author":"PLATANIAS L C","year":"2005","unstructured":"PLATANIAS L C. Mechanisms of type-I- and type-II-interferon-mediated signalling [J]. Nature reviews Immunology, 2005, 5(5): 375-86."},{"key":"e_1_3_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.11.022"},{"key":"e_1_3_2_1_34_1","volume-title":"Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors [J]. Frontiers in immunology","author":"WEBER R","year":"2018","unstructured":"WEBER R, FLEMING V, HU X, Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors [J]. Frontiers in immunology, 2018, 9(1310."},{"key":"e_1_3_2_1_35_1","volume-title":"Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab [J]. Cancer immunology, immunotherapy: CII","author":"MEYER C","year":"2014","unstructured":"MEYER C, CAGNON L, COSTA-NUNES C M, Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab [J]. Cancer immunology, immunotherapy: CII, 2014, 63(3): 247-57."},{"key":"e_1_3_2_1_36_1","volume-title":"Md","author":"ZHANG H","year":"1950","unstructured":"ZHANG H, CONRAD D M, BUTLER J J, Adenosine acts through A2 receptors to inhibit IL-2-induced tyrosine phosphorylation of STAT5 in T lymphocytes: role of cyclic adenosine 3',5'-monophosphate and phosphatases [J]. Journal of immunology (Baltimore, Md: 1950), 2004, 173(2): 932-44."},{"key":"e_1_3_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aac4255"},{"key":"e_1_3_2_1_38_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao3290"},{"key":"e_1_3_2_1_39_1","volume-title":"Neural regulation of drug resistance in cancer treatment [J]. Biochimica et biophysica acta Reviews on cancer","author":"LIU D","year":"2019","unstructured":"LIU D, LI X, CHEN X, Neural regulation of drug resistance in cancer treatment [J]. Biochimica et biophysica acta Reviews on cancer, 2019, 1871(1): 20-8."},{"key":"e_1_3_2_1_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.05.005"}],"event":{"name":"ISAIMS 2022: 2022 3rd International Symposium on Artificial Intelligence for Medicine Sciences","acronym":"ISAIMS 2022","location":"Amsterdam Netherlands"},"container-title":["Proceedings of the 3rd International Symposium on Artificial Intelligence for Medicine Sciences"],"original-title":[],"link":[{"URL":"https:\/\/dl.acm.org\/doi\/10.1145\/3570773.3570784","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dl.acm.org\/doi\/pdf\/10.1145\/3570773.3570784","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T06:48:38Z","timestamp":1755845318000},"score":1,"resource":{"primary":{"URL":"https:\/\/dl.acm.org\/doi\/10.1145\/3570773.3570784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,13]]},"references-count":40,"alternative-id":["10.1145\/3570773.3570784","10.1145\/3570773"],"URL":"https:\/\/doi.org\/10.1145\/3570773.3570784","relation":{},"subject":[],"published":{"date-parts":[[2022,10,13]]},"assertion":[{"value":"2022-12-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}